Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study

The maximum tolerated dose of paclitaxel administered by 24-hour continuous infusion in children is known. Short infusion might offer equivalent antitumour efficacy and reduced haematological toxicity, without increasing the allergic risk. Our aims were to determine the maximum tolerated dose and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Doz, F, Gentet, J C, Pein, F, Frappaz, D, Chastagner, P, Moretti, S, Vassal, G, Arditti, J, Tellingen, O Van, Iliadis, A, Catalin, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363793/
https://www.ncbi.nlm.nih.gov/pubmed/11237379
http://dx.doi.org/10.1054/bjoc.2000.1637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363793/
https://www.ncbi.nlm.nih.gov/pubmed/11237379
http://dx.doi.org/10.1054/bjoc.2000.1637

Ejemplares similares